CME: On the road to eliminating pneumococcal diseases: a focus on vaccination practice in adults
ACCREDITATION EXPIRED: September 05, 2026
Activity Description / Statement of Need:
In this online, self-learning activity:
Streptococcus (S.) pneumoniae is a common bacterium and one of the leading causes of community-acquired pneumonia (CAP), causing 27% of cases worldwide and 15% of U.S. cases – an important figure because CAP is a major cause of morbidity and mortality. Not only is acute respiratory illness one of the top ten causes of death in the U.S., but it is associated with a 17% all-cause mortality rate 30 days after presentation and a 38% rate after one year. For those admitted to the ICU – accounting for nearly a quarter of those hospitalized with CAP the corresponding morality rates are 27% and 47%, respectively.
Target Audience:
HCPs including: infectious diseases and internal medicine; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and those who otherwise commonly care for or clinically encounter patients at risk for pneumococcal pneumonia.
Commercial Support Disclosure: This program is supported by an educational grant from Merck.
This activity is free of charge.
Release Date: September 05, 2024 -- Expiration Date: September 05, 2026
Faculty: Hannah Nam, MD
Agenda
|
Faculty introductions, disclosures |
|
Introduction and review of the public health challenge of pneumococcal pneumonia · Epidemiology · Pathophysiology · The health burden of pneumococcal pneumonia |
|
Prevention of pneumococcal disease: · Public health goals · Vaccine products: conjugate, polysaccharide · Adult candidates for receiving a pneumococcal vaccine o Older adults o Adults under 65 years with high-risk conditions o Impact of a previous vaccine dose · Efficacy and safety of present products · Vaccines presently in development · Barriers to pneumococcal vaccination: provider questions, vaccine hesitancy · Patient case(s) |
|
Summarize content and conclude session |
Learning Objectives
By the end of the session the participant will be able to:
- Summarize challenges related to the health burden, recognition, management, and prevention of pneumococcal pneumonia.
- Identify present and emerging pneumococcal vaccines.
- Distinguish those patients who would benefit from a pneumococcal vaccine.
Accreditation
ACCME Activity #202818491
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Disclosures of Faculty: Hannah Nam, MD, Assistant Professor of Clinical Medicine, UCI School of Medicine, has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty WILL NOT discuss off-label uses of a commercial product.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Merck.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
The present and future state of care in hereditary angioedema (HAE)
Cholangiopathy management updates with an eye on the horizon: focus on primary biliary cholangitis
The explicit need for implicit bias and cultural competence training in the health professions